Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
Helus Pharma announced that the APPROACH Phase 3 clinical trial of HLP003 for major depressive disorder has surpassed 86% enrollment. The company confirmed it remains on track for a topline data readout in the fourth quarter of 2026.
Key figures
- Drug Name
- HLP003
- Phase Of Trial
- Phase 3
- Readout timeline
- Q4 2026
- Enrollment percent
- 86%
- Response rate 12mo
- 100%
- Remission rate 12mo
- 71%
- Madrs reduction 12mo
- ~23 points
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.